Ultrasound contrast developerSonus Pharmaceuticals has licensed distribution rights for itsEchoGen intravascular agent to Daiichi Pharmaceutical of Japan.Under the agreement, Daiichi will market and distribute EchoGenin Japan and several other Asian
Ultrasound contrast developerSonus Pharmaceuticals has licensed distribution rights for itsEchoGen intravascular agent to Daiichi Pharmaceutical of Japan.Under the agreement, Daiichi will market and distribute EchoGenin Japan and several other Asian nations, Bothell, WA-based Sonusannounced last month.
Daiichi will guide clinical development of EchoGen and willmanage its registration with the Japanese Ministry of Health andWelfare. Sonus will receive milestone payments from Daiichi.
EchoGen is entering phase-two clinical trials in the U.S.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.